Risk of Hemolytic Transfusion Reactions Following Emergency-Release RBC Transfusion
نویسندگان
چکیده
منابع مشابه
Hemolytic Transfusion Reactions.
SUMMARY: The risk of hemolytic transfusion reactions (HTRs) is approximately 1:70,000 per unit. Acute HTRs occurring during or within 24 h after administration of a blood product are usually caused by transfusion of incompatible red blood cells (RBCs), and, more rarely, of a large volume of incompatible plasma. Delayed HTRs are caused by a secondary immune response to an antigen on the donor's ...
متن کاملHemolytic transfusion reactions
A hemolytic transfusion reaction (HTR) is the accelerated clearance or lysis of transfused red cells because of immunologic incompatibility. Although they may at times have similar clinical presentations, HTR is distinguished from autoimmune hemolysis or nonimmune causes of shortened survival of transfused red cells. HTR may occur when antigen-positive red cells are transfused to a patient with...
متن کاملDelayed hemolytic transfusion reactions.
Delayed hemolytic transfusion reactions continue to occur in spite of the use of all of the currently available techniques of antibody detection. Both low titers of the antibodies and dosage effects appear to contribute to the failure of detection. A rapid anamnestic response can occur with transfusion of the appropriate antigen. The clinical as well as the laboratory presentation of delayed he...
متن کاملHemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them.
When a reaction occurs during or after the transfusion of a blood product, those involved in the care of that patient tend to think first of an immunological evenł. l However, many transfusion reactions may not be immunologically mediated. The differential diagnosis of a transfusion reaction should include the many nonimmune conditions that can lead to the destruction of either donor or recipie...
متن کاملManagement of RBC-transfusion dependence.
Strategies for the management of anemia in patients with myelodysplastic syndrome (MDS) have evolved following the U.S. Food and Drug Administration (FDA) approval of three new therapeutics from one of symptom amelioration with red blood cell (RBC) transfusions to one of active treatment. Most patients develop transfusion-dependent anemia over the course of their disease, however, and its adver...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 2010
ISSN: 0002-9173,1943-7722
DOI: 10.1309/ajcp9ofjn7fltxdb